Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding

ConclusionsOur study suggests that aPCC could be an option in patients with major bleeding associated with apixaban or rivaroxaban. It may be an alternative for patients who need anticoagulation reversal if the specific antidote, andexanet alfa, is unavailable.

http://link.springer.com/10.1007/s40256-019-00383-z

Source: American Journal of Cardiovascular Drugs - November 10, 2019 Category: Cardiology Source Type: research